Jonathan Dranoff, MD
he/him/his
DownloadHi-Res Photo
Cards
Appointments
Digestive Diseases
Primary
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
About
Titles
Professor of Medicine (Digestive Diseases)
Biography
Dr. Dranoff is a professor of medicine in the Section of Digestive Diseases. Dr. Dranoff is a physician/scholar who has expertise in several areas in liver disease pathophysiology. As director of the VA Connecticut Healthcare System Steatotic Liver Disease program, he has an interests in exercise and coffee consumption as approaches to moderate the effect of steatotic liver disease. Dr. Dranoff is also interested in drug-induced liver injury, including acetaminophen safety/toxicity in patients with advanced chronic liver disease.
Appointments
Digestive Diseases
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Yale University School of Medicine (1999)
- Resident
- Boston University Medical Center (1996)
- MD
- Drexel University (1993)
- BA
- Lehigh University (1991)
Research
Overview
Medical Subject Headings (MeSH)
Acetaminophen; Chemical and Drug Induced Liver Injury; Fibrosis; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease
ORCID
0000-0003-3130-1909
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jonathan Dranoff's published research.
Publications Timeline
A big-picture view of Jonathan Dranoff's research output by year.
Research Interests
Research topics Jonathan Dranoff is interested in exploring.
Michael H Nathanson, MD, PhD
Dhanpat Jain, MD
Tamar Taddei, MD
James Lorenzen Boyer, MD, FACEP
94Publications
2,971Citations
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease
Acetaminophen
Fibrosis
Publications
2024
Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity
Tas E, Sundararajan D, Lo J, Morelli N, Garcia-Reyes Y, Ware M, Rahat H, Ou X, Na X, Sundaram S, Severn C, Pyle L, Børsheim E, Vajravelu M, Muzumdar R, Dranoff J, Cree M. Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity. Journal Of The Endocrine Society 2024, 8: bvae110. PMID: 38895640, PMCID: PMC11185182, DOI: 10.1210/jendso/bvae110.Peer-Reviewed Original ResearchConceptsMRI fat fractionMagnetic resonance imagingPolycystic ovary syndromeVibration-controlled transient elastographyTransient elastographyDiagnostic accuracyDiagnostic accuracy of transient elastographyAccuracy of transient elastographyReceiver-operating characteristic curveFat fractionHepatosteatosis groupSignificant obesityDiagnostic performanceClinical trialsYouden indexLiver diseaseChildhood obesityHigh riskSteatotic liver diseaseLiver fatObesityResonance imagingCharacteristic curveHepatosteatosisDiagnostic methodsAASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Sterling R, Patel K, Duarte-Rojo A, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology 2024 PMID: 38489523, DOI: 10.1097/hep.0000000000000845.Peer-Reviewed Original ResearchCitationsAltmetricAASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
Sterling R, Asrani S, Levine D, Duarte-Rojo A, Patel K, Fiel M, Leung D, Taouli B, Alsawas M, Murad M, Dranoff J, Taddei T, Rockey D. AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension. Hepatology 2024 PMID: 38489663, DOI: 10.1097/hep.0000000000000844.Peer-Reviewed Original ResearchCitationsAltmetricAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024 PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-infectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virusAASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Sterling R, Duarte-Rojo A, Patel K, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology 2024 PMID: 38489518, DOI: 10.1097/hep.0000000000000843.Peer-Reviewed Original ResearchCitationsAltmetric
2023
Coffee, adenosine, and the liver
Dranoff J. Coffee, adenosine, and the liver. Purinergic Signalling 2023, 20: 21-28. PMID: 37755557, PMCID: PMC10828332, DOI: 10.1007/s11302-023-09968-5.Peer-Reviewed Original ResearchCitationsEffects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial
Tas E, Landes R, Diaz E, Bai S, Ou X, Buchmann R, Na X, Muzumdar R, Børsheim E, Dranoff J. Effects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial. Obesity 2023, 31: 2740-2749. PMID: 37731271, DOI: 10.1002/oby.23887.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-intensity interval trainingCardiorespiratory fitnessOral glucose tolerance testDual-energy X-ray absorptiometryAttenuation parameter (CAP) scoreIntrahepatic triglyceride contentSerum alanine aminotransferaseGlucose tolerance testSteatotic liver diseaseX-ray absorptiometryLiver magnetic resonanceCardiometabolic markersCardiometabolic healthExercise trainingHIIT protocolsLiver diseaseLiver fatExercise protocolTolerance testCRF testAlanine aminotransferaseInterval trainingMRI-PDFFTriglyceride contentObesityCoffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects
Dranoff J. Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects. AJP Gastrointestinal And Liver Physiology 2023, 324: g419-g421. PMID: 36976807, DOI: 10.1152/ajpgi.00026.2023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsLiver diseaseLiver-related mortalityChronic liver diseaseFatty liver diseasePositive health outcomesPrimary active ingredientCoffee consumptionEpidemiological studiesHealth outcomesAdenosine receptorsBiological plausibilityDiseaseActive ingredientsPatientsAntagonistMortalityRecent publicationsReceptors
2022
Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes
Tas E, Bai S, Mak D, Diaz E, Dranoff J. Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes. Journal Of Diabetes And Its Complications 2022, 36: 108341. PMID: 36345110, DOI: 10.1016/j.jdiacomp.2022.108341.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNonalcoholic fatty liver diseaseBody mass indexMajor risk factorType 1 diabetesHDL ratioHDL cholesterolLiver diseaseClinical parametersRisk factorsCAP scoresDiagnostic performanceReceiver operator curve analysisCommon liver diseaseFatty liver diseaseNon-diabetic childrenNon-obese subjectsFindings of childrenCross-sectional studyNAFLD statusClinical characteristicsGlycemic controlObese groupObese subjectsFurther workupMass indexReview of existing evidence demonstrates that methotrexate does not cause liver fibrosis
Cheema HI, Haselow D, Dranoff JA. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. Journal Of Investigative Medicine 2022, 70: 1452-1460. PMID: 36002175, DOI: 10.1136/jim-2021-002206.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic liver diseaseLiver diseaseLiver fibrosisLiver injuryPre-existing chronic liver diseaseNon-alcoholic fatty liver diseaseLong-term methotrexateMeta-analysis portionProgressive liver injurySerial liver biopsiesFatty liver diseaseAdvanced liver fibrosisCare of patientsMetabolic liver diseaseNon-invasive assessmentComprehensive literature searchAssessment of injuryMethotrexate doseAdvanced fibrosisCommon indicationDirect causeLiver biopsyTherapeutic dosesRisk factorsInclusion criteria
Academic Achievements and Community Involvement
activity Member
Peer Review Groups and Grant Study SectionsNational Institutes of HealthDetails02/08/2021 - PresentDescriptionRegular member, DDK-C Study Sectionhonor Member
National AwardAmerican Society for Clinical InvestigationDetails02/17/2022United Stateshonor Fellow
International AwardAmerican Association for the Study of Liver DiseaseDetails02/17/2022United Stateshonor Fellow
International AwardAmerican Gastroenterological AssociationDetails02/17/2022United Stateshonor Member
National AwardAlpha Omega AlphaDetails02/17/2022United States
Links & Media
News
- March 30, 2023
New Professors Within the Department of Internal Medicine
- November 28, 2022Source: Allure
TikTok's "Blood Cleanse" Trend Is BS at Best
- December 14, 2021
Welcome New Faculty & Staff (December 2021)
Get In Touch
Contacts
Academic Office Number
Mobile Phone Number
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Locations
Hepatology Clinic; Building 2; 4th Floor
Academic Office
VA Connecticut Healthcare
950 Campbell Avenue, Wing Building 2, Fl 4, Rm 140
West Haven, CT 06516
Business Office
203.932.5711 x7232Business Office Fax
203.937.3873
Administrative Support